Wojcicki co-founded 23andMe 16 years ago, and although the company is best known for its low-cost consumer genetic testing service, it works on a variety of health care and biotechnology fronts. A test for prostate cancer risk won FDA clearance this January. 23andMe has recently launched, in partnership with GSK, a clinical trial for an immunotherapy drug. And in 2021 Wojcicki led 23andMe through an IPO that raised $592 million after the company merged with a special-purpose acquisition corporation backed by billionaire Richard Branson.
From STAT:
Industry
Age
-
48
Location
-
Mountain View, CA
